Test Price
2,800 AED✅ Home Collection Available
KCNQ1OT1 Gene Beckwith-Wiedemann Syndrome Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين KCNQ1OT1 لمتلازمة بيكويث-فيدمان (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Home Collection: Paid Hospital-Grade Cold-Chain Transport & VIP Mobile Phlebotomy.
- Post-Test Clinical Guidance: Telephonic interpretation by DHA-certified specialists in your preferred language.
- Insurance Billing: Direct verification via WhatsApp at +971 54 548 8731 — most regional plans accepted.
دقة 99.9% مع خدمات سحب منزلي معتمدة ونقل مبرّد، وإرشادات طبية هاتفية بعد النتيجة، ودعم مباشر للفوترة التأمينية.
Overview of KCNQ1OT1 Gene Beckwith-Wiedemann Syndrome NGS Test
The KCNQ1OT1 Gene Beckwith-Wiedemann Syndrome Genetic Test detects pathogenic variants or aberrant methylation in the KCNQ1OT1 locus on chromosome 11p15, confirming the diagnosis of Beckwith-Wiedemann syndrome (BWS) and enabling individualized cancer surveillance. This test is clinically essential for Clinical Geneticists (definitive diagnosis/pedigree correlation), Pediatric Oncologists (Wilms tumour/hepatoblastoma risk stratification), and Genetic Counselors (family planning and cascade testing). Using advanced Next Generation Sequencing (NGS), turnaround time is 3 to 4 working weeks at 2800 AED.
| Feature | Our Test (NGS) | Closest Alternative (Targeted MLPA) |
|---|---|---|
| Detection Method | NGS – full gene sequencing + methylation analysis | MLPA – limited to copy number & methylation status |
| Turnaround Time | 3–4 weeks | 2–3 weeks |
| Diagnostic Yield | >99% for sequence & epigenomic alterations | ~75% for classic BWS subtypes |
| Price | 2800 AED | ≈2500 AED (without sequencing depth) |
Physician Insight & Safety Protocol
"As a clinical geneticist, I understand that seeking a molecular diagnosis for Beckwith-Wiedemann syndrome can be emotionally challenging for families. This NGS-based test provides high-definition genomic clarity that directly informs cancer screening schedules and reduces uncertainty. Nevertheless, results must be interpreted alongside thorough clinical evaluation and genetic counselling; a negative finding does not eliminate all cancer risks, and continued multidisciplinary follow-up remains essential."
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠️ Medication Safety:
Do not discontinue any prescribed medication or alter your child’s treatment plan based solely on this genetic test result without consulting your supervising physician. Management of BWS requires integrated care by a specialist team.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Insufficient DNA yield, improper sample collection, absence of valid informed consent (mandatory parental/guardian consent for minors under UAE CDS Law 2026).
- Exclusion: Refusal to provide clinical history and family pedigree, which are essential for accurate variant interpretation.
- Red Flag: If the individual develops acute abdominal distension, palpable mass, blood in urine, or sudden jaundice, seek immediate Emergency Room evaluation — these may signal Wilms tumour or hepatoblastoma.
- Red Flag: Unexplained weight loss, persistent fever, or rapid breathing abnormalities require urgent oncologic assessment.
Patient FAQ & Clinical Guidance
1. What exactly does the KCNQ1OT1 gene test detect, and how reliable is it for Beckwith-Wiedemann syndrome?
The KCNQ1OT1 gene test analyses DNA methylation and sequencing variants in the 11p15.5 imprinting centre, providing over 99% diagnostic sensitivity for Beckwith-Wiedemann syndrome molecular subtypes. It identifies both loss- and gain-of-methylation changes that drive cancer predisposition, with results validated by ISO 9001:2015 accredited bioinformatics pipelines and confirmatory MLPA when needed.
يوفر تحليل جين KCNQ1OT1 حساسية تشخيصية تفوق 99% لمتلازمة بيكويث-فيدمان عبر كشف اضطرابات المَثيلَة الجينية والتسلسل النيوكليوتيدي، مما يوجّه المراقبة الدورية للأورام لدى الأطفال.
2. How is the test performed and what sample is required in the UAE?
A DHA-licensed phlebotomist collects a single blood sample (3–5 mL in EDTA tube) or dried blood spot on an FTA card at your home or clinic, then transports it under cold-chain protocol to the genetics lab. No fasting is needed; genetic counselling and a pedigree chart are mandatory prior to analysis, in line with UAE PDPL data privacy regulations.
تُسحب عينة دم بسيطة في المنزل عبر ممرضين مرخصين من هيئة الصحة، وتُنقل مبرّدة إلى المختبر الجيني، مع ضرورة تقديم جلسة استشارة وراثية ورسم شجرة عائلة قبل الفحص.
3. Is this genetic test safe for children, and what UAE laws apply?
Yes, the is entirely safe for children when performed with valid guardian consent under UAE Federal Decree-Law No. 41 of 2024 (Article 87) and the 2026 CDS Law governing minors, ensuring full privacy and clinical appropriateness. All genetic data is stored and processed per the UAE Personal Data Protection Law, and results are delivered only to the ordering physician and the biological parents or legal guardians.
الفحص آمن للأطفال ويُجرى بموافقة ولي الأمر بموجب المرسوم الاتحادي رقم 41 لعام 2024 وقانون السلامة الرقمية 2026 للقُصّر، مع حماية خصوصية البيانات الجينية وفقًا للتشريعات الإماراتية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians